DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Blood Pressure Reduction in Heart Failure

Information source: University of Sao Paulo
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Heart Failure; Cardiac Failure; Congestive Heart Failure

Intervention: Hydralazine/amlodipine (Drug); Placebo (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: University of Sao Paulo

Official(s) and/or principal investigator(s):
Edimar A Bocchi, Prof., Principal Investigator, Affiliation: Heart Institute (InCor) HC FMUSP


Previous studies have demonstrated a direct association between blood pressure level and cardiovascular risk. However in patients with heart failure this association is considered controversial. The aim of this study is to evaluate the effect of the reduction of blood pressure in patients with heart failure. The investigators will examine the effects of this intervention over mortality, quality of life, and cardiac function.

Clinical Details

Official title: Effect of Blood Pressure Reduction in Patients With Chronic Heart Failure - Randomized, Double-blind, Placebo-controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome:

Any cause mortality

Unplanned hospital admission from any cause

Secondary outcome:

Cardiovascular death

Acute myocardial ischemia


Symptomatic hypotension

Renal function

Peak exercise oxygen consumption

Quality of life


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- stable chronic heart failure for at least 6 months

- ejection fraction of 40% or less, as measured by transthoracic echocardiography

- optimal clinical treatment for chronic heart failure according to current

international guidelines. Exclusion Criteria:

- patient refusal

- rheumatic or degenerative valvular disease

- restrictive cardiomyopathy

- evidence of myocardial ischemia

- alcohol or drug use

- malignant neoplasm

- active infection

- surgical intervention in the 3 previous months

- lactation, childbearing or childbearing potential.

- pulmonary embolism in the 6 previous months

Locations and Contacts

Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP 05403000, Brazil
Additional Information

Starting date: January 2011
Last updated: June 6, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017